AstraZeneca and BMS Receive Award from Major Medical Association
News May 09, 2013
The ACE Philanthropic Award is presented to an industry partner who is a member of the Corporate AACE Partnership (CAP) and has made a charitable contribution to ACE in support of the betterment of endocrine care and public health.
AstraZeneca and Bristol-Myers Squibb formed the diabetes alliance and entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for Type 2 Diabetes.
“The AstraZeneca/Bristol-Myers Squibb Diabetes Alliance is honored to be recognized with the ACE Philanthropic Award,” said Shoba Ravichandran, M.D., Group Director, AstraZeneca/Bristol–Myers Squibb Diabetes Alliance. “We share the association’s mission of providing high quality care to patients and supporting clinicians, educators and scientists in their work to overcome the burdens of diabetes and other endocrine related diseases.”
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018